117 related articles for article (PubMed ID: 11091601)
1. Multidrug Resistance and Prodrug Activation for Cancer Gene Therapy of Breast Cancer.
Fujii T; Fu SQ; Yin LH; Nanakorn T; Sanchez FG; Cooperberg M; Guo D; Wang T; D L; Pizzorno G; Deisseroth A
Breast Cancer; 1997 Dec; 4(4):210-212. PubMed ID: 11091601
[TBL] [Abstract][Full Text] [Related]
2. Prodrug activation enzymes in cancer gene therapy.
Aghi M; Hochberg F; Breakefield XO
J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for carcinoma of the breast.
Stoff-Khalili MA; Dall P; Curiel DT
Cancer Gene Ther; 2006 Jul; 13(7):633-47. PubMed ID: 16410823
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for colon cancer.
Zwacka RM; Dunlop MG
Hematol Oncol Clin North Am; 1998 Jun; 12(3):595-615. PubMed ID: 9684100
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model.
Hanania EG; Deisseroth AB
Clin Cancer Res; 1997 Feb; 3(2):281-6. PubMed ID: 9815684
[TBL] [Abstract][Full Text] [Related]
6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
7. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
8. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
9. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
10. How to overcome (and exploit) tumor hypoxia for targeted gene therapy.
Greco O; Marples B; Joiner MC; Scott SD
J Cell Physiol; 2003 Dec; 197(3):312-25. PubMed ID: 14566961
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for the treatment of cancer.
Buchsbaum DJ; Curiel DT
Cancer Biother Radiopharm; 2001 Aug; 16(4):275-88. PubMed ID: 11602998
[TBL] [Abstract][Full Text] [Related]
12. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
14. Results of retroviral and adenoviral approaches to cancer gene therapy.
Yin LH; Fu SQ; Nanakorn T; Garcia-Sanchez F; Chung I; Cote R; Pizzorno G; Hanania E; Heimfeld S; Crystal R; Deisseroth A
Stem Cells; 1998; 16 Suppl 1():247-50. PubMed ID: 11012168
[TBL] [Abstract][Full Text] [Related]
15. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.
Sanlioglu AD; Dirice E; Aydin C; Erin N; Koksoy S; Sanlioglu S
BMC Cancer; 2005 May; 5():54. PubMed ID: 15916713
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated targeted gene therapy for breast cancer and for purging hematopoietic stem-cell sources.
Chen L
Methods Mol Med; 2000; 35():361-9. PubMed ID: 21390817
[TBL] [Abstract][Full Text] [Related]
17. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
18. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1.
Yang G; Wu D; Zhu J; Jiang O; Shi Q; Tian J; Weng Y
Oncol Rep; 2013 Aug; 30(2):877-89. PubMed ID: 23760062
[TBL] [Abstract][Full Text] [Related]
20. Redox-triggered mitoxantrone prodrug micelles for overcoming multidrug-resistant breast cancer.
Qiao H; Zhu Z; Fang D; Sun Y; Kang C; Di L; Zhang L; Gao Y
J Drug Target; 2018 Jan; 26(1):75-85. PubMed ID: 28583001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
